Wanbury Limited

BSE: WANBURY524212ISIN INE107F01022

Healthcare
Pharmaceuticals
BSE Healthcare

Share price

₹192.55-0.10 (-0.05%)

as of 4 Nov 2026

Prices adjusted for splits and bonuses; cash dividends excluded. Volume shows actual shares traded.

52W high: ₹360.00
52W low: ₹162.00
Off 52W high: -46.51%
1M return: +1.72%
3M return: -30.94%
6M return: -25.31%
1Y return: -27.84%
20D avg volume: 12,783
50 DMA: ₹215.49
200 DMA: ₹249.79

Key ratios Consolidated

Market cap: ₹673.29 Cr
Current price: ₹192.55
52W high / low: ₹360.00 / ₹162.00
Face value: ₹10.00
P/E: 0.00
P/B: —
EPS (TTM): ₹0.00
Book value / share: —
ROE: —
ROCE: 27.80%
Operating margin: —
Net margin: —
Debt / equity: 2.92
Net debt: ₹169.17 Cr
Interest cover: 1.80
Dividend yield: —
Dividend / share (TTM): —
Payout: —
Cash conversion cycle: 8.1 days

Financials

Metric	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24	Q1 FY24	Q4 FY23	Q3 FY23	Q2 FY23
Income statement
	163.18	172.00	133.45	161.19	131.11	139.41	145.50	144.46	146.28	132.97	125.78	123.95
	0.35	1.84	0.84	1.63	0.94	0.93	0.69	0.76	0.62	2.06	0.26	0.78
	163.53	173.84	134.29	162.82	132.05	140.33	146.19	145.22	146.90	130.91	126.04	124.74
	149.93	154.79	133.00	154.66	131.01	131.98	135.93	138.03	141.91	129.40	129.08	125.45
	72.78	75.95	60.91	76.82	64.20	66.87	63.85	75.75	82.75	64.45	65.76	64.40
	3.10	3.89	4.71	3.20	3.28	3.98	6.51	3.65	3.17	2.22	6.76	3.83
	28.69	26.42	26.31	26.35	25.15	20.14	24.63	21.07	21.08	20.70	19.18	19.61
	7.54	9.04	10.17	10.15	7.59	7.46	8.26	7.67	5.79	7.51	6.63	3.94
	3.64	3.37	3.32	3.32	3.29	3.28	3.32	3.24	3.19	3.07	3.13	3.15
	34.71	31.63	31.32	32.81	28.73	30.68	28.89	29.69	26.83	23.82	23.78	22.65
	13.61	19.05	1.29	8.17	1.04	8.35	10.26	7.19	4.99	1.51	-3.04	-0.71
	0.00	0.00	0.00	0.00	0.00	25.56	0.00	0.00	0.00	-0.59	0.00	0.00
	13.61	19.05	1.29	8.17	1.04	33.91	10.26	7.19	4.99	0.92	-3.04	-0.71
	0.12	-1.20	0.07	0.15	0.00	0.27	0.02	0.18	0.30	0.10	0.23	0.18
	13.49	20.26	1.22	8.02	1.04	33.63	10.27	7.36	4.69	1.02	-3.28	-0.89
	4.12	6.18	0.38	2.44	0.32	2.47	3.13	2.25	1.43	0.49	-1.00	-0.27
Key metrics
	24.79	31.46	14.78	21.64	11.92	44.65	21.84	18.10	13.97	11.50	6.72	6.38
	15.20%	18.30%	11.10%	13.40%	9.10%	32.00%	15.00%	12.50%	9.60%	8.60%	5.30%	5.10%
	8.30%	11.80%	0.90%	5.00%	0.80%	24.10%	7.10%	5.10%	3.20%	0.80%	-2.60%	-0.70%
	—	11.70%	—	—	—	—	—	—	—	—	—	—
	24.50%	23.40%	-8.30%	11.60%	-10.40%	4.80%	15.70%	16.50%	—	—	—	—
	1,197.10%	-39.80%	-88.10%	9.00%	-77.80%	3,197.10%	413.10%	927.00%	—	—	—	—

Metric	TTM	FY25	FY24	FY23	FY22
Income statement
	629.82	599.51	575.65	499.65	511.19
	4.66	3.49	2.99	0.91	1.51
	634.48	603.01	578.64	500.56	512.69
	592.38	573.46	547.86	510.25	507.93
	286.46	277.88	289.22	257.48	304.93
	14.90	15.08	17.30	15.98	20.14
	107.77	104.24	86.92	81.00	74.81
	36.90	36.95	29.18	21.39	20.61
	13.65	13.31	13.03	12.38	11.45
	130.47	124.49	116.09	92.88	100.78
	42.12	29.55	30.78	-9.69	4.76
	0.00	0.00	25.56	-0.59	76.37
	42.12	29.55	56.34	-10.29	81.13
	-0.86	-0.98	0.38	0.11	0.35
	42.99	30.53	55.96	-10.40	81.47
	13.12	9.32	9.29	-3.00	25.29
Key metrics
	92.67	79.81	98.55	23.48	113.19
	14.71%	13.30%	17.10%	4.70%	22.10%
	6.83%	5.10%	9.70%	-2.10%	15.90%
	—	27.80%	—	—	—
	12.37%	4.10%	15.20%	-2.30%	—
	-17.80%	-45.40%	638.10%	-112.80%	—
	—	-22.93	—	—	—
	—	0.85	—	—	—
	—	2.92	—	—	—
	—	169.17	—	—	—
	—	8.1	—	—	—
Balance sheet
	—	413.92	—	—	—
	—	193.44	—	—	—
	—	4.06	—	—	—
	—	114.16	—	—	—
	—	37.68	—	—	—
	—	26.54	—	—	—
	—	189.69	—	—	—
	—	138.46	—	—	—
	—	174.61	—	—	—
	—	173.23	—	—	—
	—	12.94	—	—	—
	—	160.29	—	—	—
	—	59.27	—	—	—
Cash flow
	—	26.10	—	—	—
	—	-51.17	—	—	—
	—	25.73	—	—	—
	—	49.03	—	—	—

Metric	Q1 FY27	Q4 FY26	Q3 FY26	Q2 FY26	Q1 FY26	Q4 FY25	Q3 FY25	Q2 FY25	Q1 FY25	Q4 FY24	Q3 FY24	Q2 FY24
Income statement
	165.58	164.58	162.45	160.06	163.18	172.00	133.45	161.19	131.11	139.41	145.50	144.46
	0.36	0.21	0.18	0.20	0.35	1.84	0.84	1.63	0.94	0.93	0.69	0.76
	165.94	164.79	162.63	160.26	163.53	173.84	134.29	162.82	132.05	140.33	146.19	145.22
	161.36	146.01	146.76	145.10	149.93	154.79	133.00	154.66	131.01	131.98	135.93	138.03
	73.97	62.95	66.51	70.66	72.78	75.95	60.91	76.82	64.20	66.87	63.85	75.75
	2.68	2.82	6.06	4.64	3.10	3.89	4.71	3.20	3.28	3.98	6.51	3.65
	35.38	29.68	31.84	29.43	28.69	26.42	26.31	26.35	25.15	20.14	24.63	21.07
	7.97	8.06	7.26	7.12	7.54	9.04	10.17	10.15	7.59	7.46	8.26	7.67
	4.04	3.23	3.74	3.70	3.64	3.37	3.32	3.32	3.29	3.28	3.32	3.24
	34.97	39.74	35.13	37.79	34.71	31.63	31.32	32.81	28.73	30.68	28.89	29.69
	4.59	18.77	15.87	15.16	13.61	19.05	1.29	8.17	1.04	8.35	10.26	7.19
	0.00	-3.60	0.00	0.00	0.00	0.00	—	—	—	—	—	—
	4.59	15.17	15.87	15.16	13.61	19.05	1.29	8.17	1.04	8.35	10.26	7.19
	1.34	6.54	0.11	-0.02	0.12	-1.20	0.07	0.15	—	0.27	0.02	0.18
	3.24	21.70	15.76	15.18	13.49	20.26	1.22	8.02	1.04	8.08	10.27	7.36
	0.93	7.33	4.52	4.58	4.12	6.18	0.38	2.44	0.32	2.47	3.14	2.25
Key metrics
	16.60	26.46	26.87	25.98	24.79	31.46	14.78	21.64	11.92	19.09	21.84	18.10
	10.00%	16.10%	16.50%	16.20%	15.20%	18.30%	11.10%	13.40%	9.10%	13.70%	15.00%	12.50%
	2.00%	13.20%	9.70%	9.50%	8.30%	11.80%	0.90%	5.00%	0.80%	5.80%	7.10%	5.10%
	—	7.30%	—	8.20%	—	11.70%	—	—	—	—	—	—
	1.50%	-4.30%	21.70%	-0.70%	24.50%	23.40%	-8.30%	11.60%	—	—	—	—
	-76.00%	7.10%	1,191.80%	89.30%	1,197.10%	150.70%	-88.10%	9.00%	—	—	—	—

Metric	TTM	FY26	FY25	FY24	FY23	FY22
Income statement
	652.67	650.27	599.51	575.65	499.65	511.19
	0.95	0.94	3.49	2.99	0.91	1.51
	653.62	651.21	603.01	578.64	500.56	512.69
	599.23	587.80	573.46	547.86	510.25	507.93
	274.09	272.90	277.88	289.22	257.48	304.93
	16.20	16.62	15.08	17.30	15.98	20.14
	126.33	119.64	104.24	86.92	81.00	74.81
	30.41	29.98	36.95	29.18	21.39	20.61
	14.71	14.31	13.31	13.03	12.38	11.45
	147.63	147.37	124.49	116.09	92.88	100.77
	54.39	63.41	29.55	30.78	-9.69	4.76
	-3.60	-3.60	0.00	—	-0.59	76.37
	50.79	59.80	29.55	30.78	-10.29	81.13
	7.97	-6.33	-0.98	0.38	0.11	0.35
	55.88	66.14	30.53	30.40	-10.40	81.47
	17.36	20.55	9.32	9.29	-3.00	25.29
Key metrics
	95.91	104.09	79.81	72.99	23.48	113.19
	14.70%	16.00%	13.30%	12.70%	4.70%	22.10%
	8.56%	10.20%	5.10%	5.30%	-2.10%	15.90%
	—	28.40%	27.80%	—	—	—
	3.63%	8.50%	4.10%	15.20%	-2.30%	—
	29.98%	116.60%	0.40%	392.30%	-112.80%	—
	—	-27.53	-22.93	—	—	—
	—	0.48	0.85	—	—	—
	—	1.49	2.92	—	—	—
	—	213.84	169.17	—	—	—
	—	48.6	8.1	—	—	—
Balance sheet
	—	517.67	413.92	—	—	—
	—	238.56	193.44	—	—	—
	—	1.61	4.06	—	—	—
	—	143.28	114.16	—	—	—
	—	50.63	37.68	—	—	—
	—	34.32	26.54	—	—	—
	—	226.51	189.69	—	—	—
	—	107.25	138.46	—	—	—
	—	201.04	174.61	—	—	—
	—	215.45	173.23	—	—	—
	—	68.30	12.94	—	—	—
	—	147.15	160.29	—	—	—
	—	144.45	59.27	—	—	—
Cash flow
	—	31.53	26.10	—	—	—
	—	-56.40	-51.17	—	—	—
	—	22.42	25.73	—	—	—
	—	59.06	49.03	—	—	—

Compounded growth

Standalone

Sales CAGR 3Y: +9.18%
Sales CAGR 5Y: —
Profit CAGR 3Y: —
Profit CAGR 5Y: —
Sales YoY (TTM): +3.63%
Profit YoY (TTM): +29.98%

Consolidated

Sales CAGR 3Y: +5.46%
Sales CAGR 5Y: —
Profit CAGR 3Y: -27.90%
Profit CAGR 5Y: —
Sales YoY (TTM): +12.37%
Profit YoY (TTM): -17.80%

Compounded from reported annual figures. We publish no share-price CAGR: our prices are as-traded, so one would be wrong across every split and bonus issue.

Shareholding as of 30 Sep 2026

Promoter holding: 42.98%

Quarter	September 2026	June 2026
Promoter %	42.98%	43.01%

Holder	Type	Holding	Previous	Change
EXPERT CHEMICALS (INDIA) PVT LTD	Promoter	34.33%	34.36%	-0.03%
KINGSBURY INVESTMENTS INC	Promoter Group	8.65%	8.65%	0.00%
SURESH BHATIA	Public	3.11%	3.11%	0.00%
AUTHUM INVESTMENT AND INFRASTRUCTURE LIMITED	Public	2.08%	2.07%	+0.01%
SHARMIN NASSER	Public	1.24%	1.33%	-0.09%
BASAVA SANKARARAO KOLLI	Public	1.16%	1.16%	0.00%

Public shareholders are disclosed individually only above 1%.

Peer comparison

Company	Mkt cap (₹ Cr)	Price (₹)	P/E	ROCE	Sales YoY	Profit YoY	1Y return
Sun Pharmaceutical Industries Ltd.	4,26,112	1,776.00	38.78	17.90%	+12.13% TTM	+4.79% TTM	+4.92%
Divi's Laboratories Ltd.	2,66,424	10,036.00	91.09	19.00%	+16.35% TTM	+26.84% TTM	+47.61%
Torrent Pharmaceuticals Ltd.	1,79,908	4,730.00	85.71	9.10%	+42.06% TTM	-1.92% TTM	+32.24%
Laurus Labs Limited	1,24,601	2,306.10	93.53	19.70%	+23.03% TTM	+95.38% TTM	+134.59%
Zydus Lifesciences Limited	1,18,703	1,190.00	25.85	19.20%	+21.11% TTM	-2.51% TTM	+22.32%
Dr. Reddy's Laboratories Ltd.	1,14,513	1,372.00	41.50	13.90%	-3.53% TTM	-51.90% TTM	+14.26%
Cipla Ltd.	1,13,110	1,400.10	39.63	14.90%	-0.74% TTM	-47.48% TTM	-6.88%
Mankind Pharma Limited	1,04,631	2,533.15	46.22	13.70%	+13.27% TTM	+27.60% TTM	+6.91%
Aurobindo Pharma Ltd.	97,878	1,701.10	26.38	13.60%	+9.09% TTM	+9.48% TTM	+47.79%
Lupin Ltd	92,145	2,015.00	17.65	28.40%	+24.22% TTM	+20.10% TTM	+0.84%
Glenmark Pharmaceuticals ltd	70,608	2,501.85	39.27	16.20%	+32.94% TTM	+138.48% TTM	+35.48%
Alkem Laboratories Limited	62,054	5,190.00	28.15	18.80%	+13.36% TTM	-5.52% TTM	-8.38%
Abbott India Ltd. S	57,685	27,146.85	35.73	41.90%	+6.29% TTM	+11.18% TTM	-7.56%
Biocon Ltd.	56,061	344.00	134.63	2.90%	+5.70% TTM	-55.37% TTM	-9.53%
Gland Pharma Limited	52,105	3,157.70	46.16	13.70%	+17.57% TTM	+46.55% TTM	+65.09%
Ipca Laboratories Ltd.	50,051	1,973.15	36.40	16.40%	+10.59% TTM	+67.91% TTM	+52.33%
GlaxoSmithkline Pharmaceuticals Ltd.	42,904	2,532.60	37.42	55.40%	+12.12% TTM	+20.03% TTM	-4.84%
Ajanta Pharma Ltd.	41,406	3,313.55	32.79	29.40%	+25.01% TTM	+29.70% TTM	+26.89%
Emcure Pharmaceuticals Limited	41,254	2,174.55	37.75	25.10%	+21.12% TTM	+33.34% TTM	+64.07%
J.B. Chemicals & Pharmaceuticals Lt	38,731	2,412.25	47.77	21.90%	+5.87% TTM	+7.56% TTM	+45.79%
Sai Life Sciences Limited	32,855	1,546.30	90.80	18.10%	—	—	+67.49%
PIRAMAL PHARMA LIMITED	31,659	237.80	-151.21	0.80%	+9.43% TTM	-781.93% TTM	+18.60%
ACUTAAS CHEMICALS LIMITED	30,928	3,777.65	70.51	27.70%	+45.18% TTM	+95.78% TTM	+106.30%
Wockhardt Ltd	30,869	1,899.80	76.22	6.40%	+25.70% TTM	+894.12% TTM	+39.18%
RUBICON RESEARCH LIMITED	28,416	1,716.55	98.59	24.30%	—	—	+164.06%
Wanbury Limited	673	192.55	—	27.80%	+12.37% TTM	-17.80% TTM	-27.84%

Filings & corporate actions

Recent announcements

Financial Results as on 30th September, 20264 Nov 2026 · Result / Financial Results
Outcome of the Board Meeting held on November 04, 20264 Nov 2026 · Board Meeting / Outcome of Board Meeting
Wanbury Limited receives Australian TGA GMP Compliance Certificate for its Tanuku Plant, Strengthening Its Global Pharmaceutical Manufacturing Credentials.30 Oct 2026 · Company Update / Press Release / Media Release
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 04/11/2026 ,inter alia, to consider and approve the un-audited Financial Results (Standalone ....28 Oct 2026 · Board Meeting / Board Meeting
Wanbury Limited Awards for Tanuku and Patalganga Facilities19 Oct 2026 · Company Update / Press Release / Media Release
Wanbury Limited - Regulatory Progress in API Business, New Business Opportunities and Operational Achievements16 Oct 2026 · Company Update / Press Release / Media Release
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysolftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.12 Oct 2026 · Company Update / Press Release / Media Release (Revised)
Wanbury Skin Health Limited (Subsidiary of Wanbury Limited) Launches its berrysoftTM baby Product Range Across Multiple States in India, Marks Strategic Entry in The Paediatric Dermatology Segment.12 Oct 2026 · Company Update / Press Release / Media Release
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.9 Oct 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Press Release regarding filing new Drug Master File (DMF) in South Africa for Tramadol HC1 API.8 Oct 2026 · Company Update / Press Release / Media Release
Trading Window Closure for the Quarter ended 30th September, 2026.29 Sep 2026 · Insider Trading / SAST / Closure of Trading Window
Scrutinizer Report and Voting Results25 Sep 2026 · AGM/EGM / AGM
Change in Management24 Sep 2026 · Company Update / Change in Management
Proceedings of the 38th Annual General Meeting of the Company held on Thursday, September 24, 2026 through VC/OAVM24 Sep 2026 · AGM/EGM / AGM
Newspaper Clipping - Information regarding 38th Annual General Meeting to be held through VC/OAVM.2 Sep 2026 · Company Update / Newspaper Publication
The register of members and share transfer books of the Company will remain closed from Friday, 18 September, 2026 to Thursday, 24 September, 2026 (both days inclusive) for the purpose ....31 Aug 2026 · Corp. Action / Book Closure
Annual Report 2025-26 and Notice of the 38th Annual General Meeting of Wanbury Limited.31 Aug 2026 · Others / Reg. 34 (1) Annual Report
Notice of the 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11:30 A.M. through Video Conferencing( VC)/Other Audio Visual Means (OAVM).31 Aug 2026 · AGM/EGM / AGM
Newspaper Publication - Information regarding 38th Annual General Meeting to be held on Thursday, September 24, 2026 at 11.30 A.M.28 Aug 2026 · Company Update / Newspaper Publication
Press Release regarding EDQM approval for new product Rivaroxaban API, USFDA DMF Clearances.13 Aug 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Company Update / Allotment of ESOP / ESPS
Press Release on Un-audited Financial Results for the quarter ended 30th June, 202611 Aug 2026 · Company Update / Press Release / Media Release
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Company Update / Change in Management
Financial Results for the first quarter ended 30th June, 202611 Aug 2026 · Result / Financial Results
Outcome of the Board Meeting held on August 11, 202611 Aug 2026 · Board Meeting / Outcome of Board Meeting
Wanbury Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 11/08/2026 ,inter alia, to consider and approve Notice is hereby given pursuant to ....3 Aug 2026 · Board Meeting / Board Meeting
Press Release - No DMF deficiency letter received from the office of USFDA for multiple ANDAs30 Jul 2026 · Company Update / Press Release / Media Release
Intimation of completion of inspection by the United States Food and Drug Administration (USFDA) at the Company''s Facilty.22 Jul 2026 · Company Update / General
A Current Good Manufacturing Practices (cGMP) inspection was conducted by the United States Food and Drug Administration (USFDA) at the Company''s facility at Tanuku, West Godavari District, ....20 Jul 2026 · Company Update / General
We would like to inform you that the relevant information required to be disclosed under applicable laws has already been disclosed to the stock exhange from time to time in the recent ....17 Jul 2026 · Company Update / General
The Exchange has sought clarification from Wanbury Ltd on July 16, 2026 with reference to significant movement in price, in order to ensure that investors have latest relevant information ....16 Jul 2026 · Company Update / Clarification
Resolution passed through circulation by the Board of Directors of the Company regarding early redemption in full of 12.5% secured, guaranteed, senior, taxable, non-cumulative, unrated, ....15 Jul 2026 · Company Update / General
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd13 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd9 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Catalyst Trusteeship Ltd9 Jul 2026 · Insider Trading / SAST / Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
Certificate pursuant to Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018.7 Jul 2026 · Company Update / Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
Investor Presentation on Audited Financial Results (AFR) for the quarter and year ended 31st March, 2026 and is also available on the website of the Company at www.wanbury.com1 Jul 2026 · Company Update / Investor Presentation
Outcome of the Board Meeting - Change in Management26 Jun 2026 · Company Update / Change in Management
Outcome of the Board Meeting dated 26.06.202626 Jun 2026 · Others / Outcome without intimation
Closure of Trading Window25 Jun 2026 · Insider Trading / SAST / Closure of Trading Window

Corporate actions

Purpose	Ex date	Record date	Payment date
E.G.M.	13 Feb 2025	—	—

Board meetings

4 Nov 2026 Board Meeting - Financial Results
11 Aug 2026 Board Meeting - Financial Results